Comment on myasthenia gravis associated with TNF‐α receptor blockers: A multifaceted issue | Zendy

Galassi Giuliana | Zendy; Ariatti Alessandra | Zendy; Codeluppi Luca | Zendy; Meletti Stephano | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Premium

Comment on myasthenia gravis associated with TNF‐α receptor blockers: A multifaceted issue

Author(s) -

Galassi Giuliana,

Ariatti Alessandra,

Codeluppi Luca,

Meletti Stephano

Publication year - 2010

Publication title -

muscle and nerve

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.025

H-Index - 145

eISSN - 1097-4598

pISSN - 0148-639X

DOI - 10.1002/mus.21748

Subject(s) - neurology , medicine , clinical neurology , psychology , neuroscience , psychiatry

Fee and Kasarskis12 described a 66-yearold- diabetic man who developed facial weakness and bulbar signs after 6 years of etanercept therapy for rheumatoid arthritis. The patient had an elevated titer of acetylcholine receptor antibodies (AChR-Ab), and electrophysiologic studies suggested a disorder of neuromuscular transmission associated with axonal polyneuropathy. No immunomodulating therapy was given. After 3–8 months off etanercept his clinical and electrophysiologic features improved, but AChR-Ab titer remained elevated. We recently encountered a 68-year-old woman who experienced fluctuating fatigability 7–8 months after starting etanercept (Enbrel; Wyeth Lederle SpA) taken weekly (50 mg autoinjected subcutaneously) to treat psoriatic arthritis

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here

Accelerating Research